 |
Quotes delayed 20 minutes
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Thursday, January 21, 8:32 AM
Slide #294. Harvard Apparatus Regenerative Technology, Inc. — Preferred Stock Offering
| Company: |
Harvard Apparatus Regenerative Technology, Inc. (NYSE:HART) |
| Date announced: |
2/11/2015 |
| Shares Offered: |
695,857 |
| Date of Pricing: |
2/12/2015 |
| Price Per Share: |
$8.75 |
| Preferred Stock Offering Details: |
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced that it is proposing to offer shares of its common stock and Series B Convertible Preferred Stock ("Series B") in an underwritten public offering. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. HART expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
Harvard Apparatus Regenerative Technology is a clinical stage biotechnology company. Co. is engaged in the development and commercialization of regenerated organs for human transplant. Co.'s product, the HART-Trachea, is designed to be used to restore the structure and/or function of a damaged trachea (windpipe). The HART-Trachea is comprised of the patient's own bone marrow cells seeded on Co.'s proprietary InBreath porous plastic scaffold in its proprietary InBreath organ bioreactor. The HART-Trachea consists of three main components: a scaffold, the patient's cells and a bioreactor.
 Open the HART Page at Preferred Stock Channel »
Open the HART Page at Preferred Stock Channel (in a new window) »
|
|
